3-Methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid, 95.0%, 5g

1-(Pyrimidin-2-yl)pyrrolidin-3-amine dihydrochloride, 98+%, 500mg

2-Ethyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 95.0%, 5g

Methyl Cyanoacetate>99.0%(GC)500mL

3,4-Dimethoxy-3-cyclobutene-1,2-dione>98.0%(GC)25g

N-3-Pyridinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methyl]-1-piperidinecarboxamide, 98%, 1g

tert-Butyl 5,7-dichloro-6-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate, 98%, 100mg

(R)-1-N-Boc-3-Hydroxy-pyrrolidine, 97.0%, 100g

4-methyl-2-oxo-1,3-dioxane, 95%, 250mg

GC capillary column ROTI®Cap-1, 30 m, 0.25 mm, 0.10 µm, 1 Piece(s)

2-(2,6-Dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione, 95.0%, 250mg

tert-Butyl 4-hydroxybenzoate, 95.0%, 10g

Carbamic acid, N-[(1S)-2-[[4-[3-[5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl]-1-(1-methylethyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-1-methylethyl]-, methyl ester, 25mg